目的 探討燈盞花素注射液聯(lián)合阿司匹林治療急性缺血性腦梗死的臨床效果。方法 收集延安大學(xué)咸陽醫(yī)院2012年1月-2015年3月收治的急性腦梗死患者300例,隨機分為觀察組和對照組各150例。對照組采用急性缺血性腦梗死對癥治療,觀察組在對癥治療的基礎(chǔ)上,加用燈盞花素注射液和口服阿司匹林進行治療。兩組治療前后采用美國國立衛(wèi)生研究所腦卒中評分表(NIHSS)進行評分;采用酶聯(lián)免疫吸附試驗檢測血清白介素-6(IL-6)和腫瘤壞死因子(TNF-α)水平。治療4周后,對兩組進行臨床療效判定。結(jié)果 觀察組與對照組治療前NIHSS評分比較,差異無統(tǒng)計學(xué)意義,而治療后觀察組NIHSS評分低于對照組,差異具有統(tǒng)計學(xué)意義(P<0.05);治療后,兩組IL-6和TNF-α水平均低于治療前,差異具有統(tǒng)計學(xué)意義(P<0.05);且觀察組中IL-6和TNF-α水平均低于對照組,差異具有統(tǒng)計學(xué)意義(P<0.05);觀察組臨床總有效率達92.67%,高于對照組的78.00%,差異具有統(tǒng)計學(xué)意義(P<0.05)。結(jié)論 在急性缺血性腦梗死患者中,應(yīng)用燈盞花素注射液聯(lián)合阿司匹林腸溶片能夠改善臨床癥狀,降低炎癥因子水平,顯著提高臨床療效,值得推廣。

Objective To investigate the clinical effect of Breviscapine Injection combined with aspirin in the treatment of acute ischemic cerebral infarction. Methods Totally 300 cases of acute cerebral infarction patients in Xianyang Hospital of Yanan University from January 2012 to March 2015 were randomly divided into observation and control groups with 150 cases in each group. Patients in control group were treated with acute ischemic cerebral infarction. The patients in observation group were treated with Breviscapine Injection and oral aspirin based on symptomatic treatment. The two groups before and after treatment were scored by the National Institutes of Health Stroke Scale (NIHSS) score. Serum levels of IL-6 and TNF-α were detected by enzyme-linked immunosorbent assay (ELISA). After treatment for 4 weeks, the clinical efficacies of two groups were determined. Results There were no statistical significance in comparison on NIHSS scores between observation group and control group before treatment. Compared with the control group, the NIHSS score of observation group was lower after treatment (P<0.05). After treatment, the levels of IL-6 and TNF-α in two groups were significantly lower than that before treatment (P<0.05), and the levels of IL-6 and TNF-α in observation group were significantly lower than those in control group (P<0.05). The total effective rate of observation group was 92.67%, higher than 78.00% of control group, and the difference was statistically significant (P<0.05). Conclusion In patients with acute ischemic cerebral infarction, application of Erigeron Breviscapine Injection in combination with aspirin enteric coated tablets can improve the clinical symptoms, reduce the level of inflammatory factors, and significantly improve the clinical efficacy, which is worthy to be popularized.